EUCTR2016-001788-34-AT进行中（未招募）1 期
Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients - PEPPER
niversity Hospital Aachen, AöR, Dean of the Medical Faculty of the RWTH Aachen for the Managing Board of the University0 个研究点目标入组 200 人开始时间: 2018年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. the patient has a diagnosis of secondary or quaternary peritonitis.
- •2. the time of source control is within 6 h of the indication (defined as the date and time of registration for surgery or minimally invasive procedure).
- •3. sepsis and/or septic shock (according to the current sepsis guideline of the German Sepsis Society) are present.
- •4. the SOFA score is = 8.
- •5. the concentration of IL-6 is = 1000 pg/ml.
- •6. antibiotic therapy is started within 12 h after admission to the intensive care unit.
- •7. the informed consent form has been signed by the patient himself and/or his legal representative (such as his spouse, a proxy with effective power of attorney for health care or a court-appointed guardian) or by a consultant.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1. the patient has a life expectancy of less than 90 days due to medical conditions unrelated to peritonitis, sepsis and/or septic shock.
- •2. for female patients only: There is a pregnancy or the patient is breastfeeding.
- •3. the patient is a minor (<18 years).
- •4. The patient has known chronic renal dysfunction requiring dialysis (creatinine = 3.4 mg/dl or creatinine clearance = 30 mL /min /1.73 m2).
- •5. the patient has acute, primarily non-infectious pancreatitis or mediastinitis.
- •6. the BMI is > 40.
- •7. the patient has a contraindication to the study medication.
- •8. patient has participated in another drug study within the last 30 days.
- •9. the patient has a dependent or employment relationship with the sponsor or investigator.
- •10. the patient is institutionalised by court or regulatory order.
研究者
相似试验
招募中
1 期
Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patientsCTIS2024-513526-27-00niversitaetsklinikum Aachen AöR200
进行中（未招募）
1 期
Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patientsInvestigation of Pentaglobin® therapy in patients with sepsis and/or septic shock triggered by peritonitis after surgical infectious source control and simultaneous administration of antibiotics.MedDRA version: 21.1Level: LLTClassification code 10081559Term: Septic peritonitisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: PTClassification code 10040070Term: Septic shockSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10040047Term: SepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001788-34-DEniversity Hospital Aachen, AöR, Dean of the Medical Faculty of the RWTH Aachen for the Managing Board of the University200
进行中（未招募）
1 期
A randomised prospective study to investigate the efficacy of corneal collagen cross-linkage with riboflavin (vitamin B2) and ultraviolet A light (UVA) (370nm) to halt the progression of keratoconus. - UVA/B2EUCTR2006-000348-26-GBGuy's & St Thomas' NHS Foundation Trust36
已完成
不适用
A randomised prospective study to investigate the efficacy of corneal collagen cross linkage with riboflavin (vitamin B2) and ultraviolet A light (UVA) (370nm) to halt the progression of keratoconusKeratoconusISRCTN08013636Record Provided by the NHSTCT Register - 2007 Update - Department of Health36
尚未招募
不适用
Randomized prospective study to investigate the association between intestinal FDG accumulation obtained using 18F-FDG-PET/MRI and various parameters in patients taking metformin or vildagliptiType 2 diabetesJPRN-UMIN000044969Kobe university40